Attached files
file | filename |
---|---|
8-K - FORM 8-K - Lexaria Bioscience Corp. | form8k.htm |
Exhibit 99.1
Lexaria Extends Investor Relations Agreement
Kelowna, BC / December 22, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company) announces it has extended the services of Frontier Merchant Capital Group (Frontier) with a head office in Toronto, Canada, for a period of three months. Lexaria will pay CDN $25,000 + GST.
Frontier will assist the Company by increasing market awareness utilizing a number of financial market communication initiatives including media outreach, facilitating in-person introduction for the Company with institutional and retail brokers and investors in cities across Canada and the US, and more.
Lexarias unique patented technology allows for more efficient and effective absorption of certain molecules such as cannabinoids, while simultaneously masking and at times even eliminating inherent strong flavours and/or odors typical of those molecules. Lexarias technology is extremely cost effective to implement and applicable to the widest imaginable spectrum of foods.
About Lexaria
Lexaria Bioscience Corp. is a food sciences
company focused on the delivery of active compounds that can behave as
superfoods through its proprietary infusion technologies. Lexarias technology
enables higher bioavailability rates for CBD; THC; NSAIDs; Nicotine and other
molecules than is possible without lipophilic enhancement technology. This can
allow for lower overall dosing requirements and/or higher effectiveness in
active molecule delivery. Lexaria hopes to reduce other common but less healthy
ingestion methods such as smoking as it embraces the benefits of public health.
www.lexariaenergy.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience
Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Access to capital, or lack thereof, is a major
risk and there is no assurance that the Company will be able to raise required
working capital. Factors which could cause actual results to differ materially
from those estimated by the Company include, but are not limited to, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, competition, the patent application and approval process and other
factors which may be identified from time to time in the Company's public
announcements and filings. There is no assurance that the recent license
agreement, hemp oil sector, or alternative health businesses will provide any
benefit to Lexaria, or that the Company will experience any growth through
participation in these sectors or as a result of the license agreement. There is
no assurance that existing capital is sufficient for the Company's needs or that
it will be able to raise additional capital. There is no assurance that the
Company will receive all or any part of the $122,000 to $1,064,000 in
payments contemplated under the recently announced definitive license agreement.
There is no assurance that Lexaria will successfully complete any other
contemplated or existing technology license agreements, nor that Lexarias
technology will deliver any improvement in taste or bioavailability with any
reliability nor across any product category. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any hemp oil or
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever, nor that any patent application in the USA or any
other nation or under any treaty will result in the award of an actual patent;
nor that an award of any actual patent will protect against challenges from
unknown third parties. There is no assurance that any of Lexarias postulated
uses, benefits, or advantages for the patent-pending technology will in fact be
realized in any manner or in any part. No statement herein has been evaluated by
the Food and Drug Administration (FDA). ViPovaTM products are not
intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.